A non-randomized, open-label, roll-over study with self injection of adalimumab in adult Japanese subjects with rheumatoid arthritis
Phase of Trial: Phase III
Latest Information Update: 20 Jun 2011
At a glance
- Drugs Adalimumab (Primary)
- Indications Rheumatoid arthritis
- Focus Therapeutic Use
- Sponsors Abbott Laboratories
- 31 Aug 2018 Biomarkers information updated
- 03 Feb 2010 Actual end date changed from Dec 2008 to Nov 2006 as reported by ClinicalTrials.gov.
- 09 Jan 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.